Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

174 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A multicenter, phase 2 study of vascular endothelial growth factor trap (Aflibercept) in platinum- and erlotinib-resistant adenocarcinoma of the lung.
Leighl NB, Raez LE, Besse B, Rosen PJ, Barlesi F, Massarelli E, Gabrail N, Hart LL, Albain KS, Berkowitz L, Melnyk O, Shepherd FA, Sternas L, Ackerman J, Shun Z, Miller VA, Herbst RS. Leighl NB, et al. Among authors: melnyk o. J Thorac Oncol. 2010 Jul;5(7):1054-9. doi: 10.1097/jto.0b013e3181e2f7fb. J Thorac Oncol. 2010. PMID: 20593550 Free article. Clinical Trial.
Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer.
Herbst RS, O'Neill VJ, Fehrenbacher L, Belani CP, Bonomi PD, Hart L, Melnyk O, Ramies D, Lin M, Sandler A. Herbst RS, et al. Among authors: melnyk o, o neill vj. J Clin Oncol. 2007 Oct 20;25(30):4743-50. doi: 10.1200/JCO.2007.12.3026. Epub 2007 Oct 1. J Clin Oncol. 2007. PMID: 17909199 Clinical Trial.
Characterization of a candidate bcl-1 gene.
Withers DA, Harvey RC, Faust JB, Melnyk O, Carey K, Meeker TC. Withers DA, et al. Among authors: melnyk o. Mol Cell Biol. 1991 Oct;11(10):4846-53. doi: 10.1128/mcb.11.10.4846-4853.1991. Mol Cell Biol. 1991. PMID: 1833629 Free PMC article.
Randomized phase III study of canfosfamide in combination with pegylated liposomal doxorubicin compared with pegylated liposomal doxorubicin alone in platinum-resistant ovarian cancer.
Vergote I, Finkler NJ, Hall JB, Melnyk O, Edwards RP, Jones M, Keck JG, Meng L, Brown GL, Rankin EM, Burke JJ, Boccia RV, Runowicz CD, Rose PG. Vergote I, et al. Among authors: melnyk o. Int J Gynecol Cancer. 2010 Jul;20(5):772-80. doi: 10.1111/igc.0b013e3181daaf59. Int J Gynecol Cancer. 2010. PMID: 20973267 Clinical Trial.
Phase 1-2a multicenter dose-ranging study of canfosfamide in combination with carboplatin and paclitaxel as first-line therapy for patients with advanced non-small cell lung cancer.
Sequist LV, Fidias PM, Temel JS, Kolevska T, Rabin MS, Boccia RV, Burris HA, Belt RJ, Huberman MS, Melnyk O, Mills GM, Englund CW, Caldwell DC, Keck JG, Meng L, Jones M, Brown GL, Edelman MJ, Lynch TJ. Sequist LV, et al. Among authors: melnyk o. J Thorac Oncol. 2009 Nov;4(11):1389-96. doi: 10.1097/JTO.0b013e3181b6b84b. J Thorac Oncol. 2009. PMID: 19701107 Free article. Clinical Trial.
174 results